Get access

Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients

Authors

  • R P Hasserjian,

    1. James Homer-Wright Pathology Laboratory and Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA and National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Search for more papers by this author
  • H J B Goodman,

    1. James Homer-Wright Pathology Laboratory and Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA and National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Search for more papers by this author
  • H J Lachmann,

    1. James Homer-Wright Pathology Laboratory and Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA and National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Search for more papers by this author
  • A Muzikansky,

    1. James Homer-Wright Pathology Laboratory and Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA and National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Search for more papers by this author
  • P N Hawkins

    1. James Homer-Wright Pathology Laboratory and Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA and National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Search for more papers by this author

Robert P Hasserjian MD, Department of Pathology WRN 244, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. e-mail: rhasserjian@partners.org

Abstract

Aims:  Bone marrow sampling is a key investigation in the work-up of amyloid light chain (AL) amyloidosis, but the relationship between bone marrow findings and the varied phenotype and clinical outcome of AL amyloidosis is unclear. The aim was to determine if bone marrow pathological parameters at diagnosis were related to clinical behaviour in AL amyloidosis patients.

Methods and results:  Bone marrow findings, clinical features and outcome of 80 patients referred with a diagnosis of systemic AL amyloidosis were evaluated; six patients were subsequently excluded due to re-categorization as other forms of amyloidosis. At latest follow-up (median 66 months), 11 of the 18 patients with no identifiable bone marrow neoplastic cells (61%) versus only seven of the 56 patients with neoplastic plasma cells or non-Hodgkin's lymphoma (13%) were alive (P = 0.0046). However, neither the quantity of the neoplastic cells nor the serum light chain levels were correlated with amyloid burden or patient survival.

Conclusions:  Identification of a neoplastic population in the bone marrow of AL amyloidosis patients by histology and immunohistochemistry correlates with poor outcome; however, the neoplastic cell burden is not prognostically significant, suggesting that additional factors are important in determining disease behaviour in AL amyloidosis.

Ancillary